Literature DB >> 2879735

Pharmacokinetics of betaxolol in middle aged patients.

G Bianchetti, J F Thiercelin, J P Thenot.   

Abstract

The pharmacokinetics of betaxolol was studied in 8 middle-aged (40-60 years) subjects after oral (20 mg) and intravenous (10 mg) administration. The principal parameters were almost identical to those observed in young healthy volunteers. The recommended therapeutic regimen, a single daily dose of 20 mg, appears well suited for middle aged, hypertensive patients.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2879735     DOI： 10.1007/bf00606665

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  7 in total

1.  Improved determination of betaxolol in biological samples by capillary column gas chromatography.

Authors:  J Ganansia; G Gillet; P Padovani; G Bianchetti
Journal:  J Chromatogr       Date:  1983-06-10

2.  PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation.

Authors:  R Gomeni
Journal:  Comput Biol Med       Date:  1984       Impact factor: 4.589

3.  Betaxolol kinetics in hypertensive children with normal and abnormal renal function.

Authors:  R Palminteri; B M Assael; G Bianchetti; R Gomeni; A Claris-Appiani; A Edefonti; P L Morselli
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

4.  Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man.

Authors:  J F Giudicelli; M Chauvin; C Thuillez; C Richer; G Bianchetti; R Gomeni; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

5.  Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.

Authors:  S J Warrington; P Turner; J R Kilborn; G Bianchetti; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

6.  Pharmacokinetics of the new beta-adrenoceptor blocking agent betaxolol (SL 75212) in man after repeated oral administration.

Authors:  G Bianchetti; C Blatrix; R Gomeni; J R Kilborn; J Larribaud; P W Lücker; J J Thebault; S Trocherie; P L Morselli
Journal:  Arzneimittelforschung       Date:  1980

7.  Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers.

Authors:  P J Cadigan; D R London; B L Pentecost; G Bianchetti; R Gomeni; J R Kilborn; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335
  7 in total
  2 in total

1.  Placental transfer and perinatal pharmacokinetics of betaxolol.

Authors:  P L Morselli; M J Boutroy; G Bianchetti; A Zipfel; J L Boutroy; P Vert
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.